CTI Bags Cash, Turns Its Back On Zevalin
This article was originally published in The Pink Sheet Daily
Executive Summary
Buyer Spectrum downplays supplemental BLA delay in front-line non-Hodgkins lymphoma.
You may also be interested in...
Deals Of The Week: Amgen/Micromet, Celgene/Avila, Watson/Ascent
Along with three biotech acquisitions, the week in deal-making also saw the licensing of a new hepatitis C candidate with a different mechanism of action, further consolidation in the animal health field, and the end of Ipsen and Santhera’s collaboration on Alzheimer’s drug fipamezole.
Cancer Drug Zevalin May Finally Thrive Under Spectrum
The small oncology company may be able to succeed with the non-Hodgkin lymphoma drug where others have failed.
Cancer Drug Zevalin May Finally Thrive Under Spectrum
The small oncology company may be able to succeed with the non-Hodgkin lymphoma drug where others have failed.